Skip to content

NIRS to Monitor Abdominal Tissue Oxygen Saturation in Preterm Infants

NIRS to Monitor Abdominal Tissue Oxygen Saturation in Preterm Infants in an Open Mono-centric Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03706976
Acronym
CTOM-FIH
Enrollment
12
Registered
2018-10-16
Start date
2019-04-30
Completion date
2022-11-17
Last updated
2022-12-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neonatal Disorder

Brief summary

The NIRS (near infrared spectroscopy) sensor will be applied to the abdomen of the study population. To ensure good skin contact the sensor will be placed underneath the diaper. If that should not provide enough measurement stability, additional fixation will be given by employing aforementioned flexible bandage routinely employed in neonatal care. Once good skin contact is ensured, the sensor will measure aStO2 (abdominal tissue oxygen saturation) for up to seventy-two hours. The presence of this sensor will not disturb daily clinical activities or medical treatment in any way. Should good skin contact be endangered by movements, clinical interactions or such, the sensor will be removed and re-attached to the infants' abdomen as a consequence.

Interventions

The NIRS sensor will be applied to the abdomen of the study population. To ensure good skin contact the sensor will be placed underneath the diaper. If that should not provide enough measurement stability, additional fixation will be given by employing aforementioned flexible bandage routinely employed in neonatal care. Once good skin contact is ensured, the sensor will measure aStO2 for up to seventy-two hours. The presence of this sensor will not disturb daily clinical activities or medical treatment in any way. Should good skin contact be endangered by movements, clinical interactions or such, the sensor will be removed and re-attached to the infants' abdomen as a consequence.

Sponsors

Carag AG
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DEVICE_FEASIBILITY
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
No minimum to 35 Weeks
Healthy volunteers
No

Inclusion criteria

* Preterm infants with GA less than 35 0/7 weeks * Start of measurement earliest at day of life 2 for preterm infants with GA \>=30 0/7 weeks and day of life 4 otherwise. The measurement will not start after day of life 5 for all GA. * Signed Informed consent of the legal representative(s) is received after being informed. It is sufficient, if the consent form is signed by one legal representative, which is in majority of cases either the mother or the father. * Clinically stable condition. The clinical stability is to be reconfirmed before the start and checked during the measurement.

Exclusion criteria

* Injured, hypersensitive or bruised skin present on the belly, * Existence of clinical instability at any time during the investigation leads to exclusion, if ordered so by the physician entrusted with the investigation, * Any medical care equipment, e.g. patches, dressing, umbilical arterial or venous catheter, blood supply, etc., prohibiting correct placement of the sensors, * Dark skin pigmentation or dense hairiness on the belly absorbing too much light in the near infrared region to allow for NIRS, * Congenital malformations, * Severe metabolic disorders, * Early onset sepsis, * Inability of legal representatives to understand the purpose of the clinical trial due to language barriers such as the insufficient ability to understand the spoken or written language, * The treatment of newborn jaundice with light during the intended measurement time, * Previous enrolment into the current study, * Family members, employees and other dependent persons of the investigator, * Participation in another study with investigational drug/device within the preceding days and during the present study which may influence aStO2.

Design outcomes

Primary

MeasureTime frameDescription
Feasibility of aStO2 measurements in all patients72 hoursaStO2 values calculated with and without considering the presence of additional absorbers besides haemoglobin.

Secondary

MeasureTime frameDescription
Safety of the investigational device assessed by evaluation of adverse events72 hoursEvaluation of AEs (Adverse Event) with regard to the investigational device. The safety related to application and use of the NIRS sensors is aimed for.

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026